We have the largest, deepest,

ex-vivo gene therapy
data set in the world.

pipeline

Product Candidates
Severe Genetic Diseases
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
lovotibeglogene autotemcel gene therapy (lovo-cel; formerly LentiGlobinTM for sickle cell disease)†
  • PH 3 

    SCD (HGB-210)

  • PH 1/2 

    SCD (HGB-206)

BCL11A shRNA (mir)1
  • PH 1 

    Sickle Cell Disease

MULTIPLE UNDISCLOSED

  • PRE-C 

    Undisclosed

† The lovo-cel clinical program is currently on a partial clinical hold pertaining to pediatric patients (under 18) related to an adolescent patient with persistent, non-transfusion-dependent anemia. bluebird bio, Inc. continues to work with the FDA to resolve the partial hold.

bluebird bio, Inc. gene therapy for sickle cell disease is investigational and not FDA-approved. Safety and efficacy have not been established.